Faculty Collaboration Database

Cellular immune response to an engineered cell-based tumor vaccine at the vaccination site. Cell Immunol 2007 Feb;245(2):91-102

Date

06/05/2007

Pubmed ID

17543914

Pubmed Central ID

PMC1949498

DOI

10.1016/j.cellimm.2007.04.004

Scopus ID

2-s2.0-34250349688 (requires institutional sign-in at Scopus site)   5 Citations

Abstract

The engineered expression of the immune co-stimulatory molecules CD80 and CD137L on the surface of a neuroblastoma cell line converts this tumor into a cell-based cancer vaccine. The mechanism by which this vaccine activates the immune system was investigated by capturing and analyzing immune cells responding to the vaccine cell line embedded in a collagen matrix and injected subcutaneously. The vaccine induced a significant increase in the number of activated CD62L(-) CCR7(-) CD49b(+) CD8 effector memory T cells captured in the matrix. Importantly, vaccine responsive cells could be detected in the vaccine matrix within a matter of days as demonstrated by IFN-gamma production. The substitution of unmodified tumor cells for the vaccine during serial vaccination resulted in a significant decrease in activated T cells present in the matrix, indicating that immune responses at the vaccine site are a dynamic process that must be propagated by continued co-stimulation.

Author List

Zhou Q, Johnson BD, Orentas RJ

Author

Bryon D. Johnson PhD Adjunct Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

4-1BB Ligand
Animals
Antigens, CD
Antigens, Differentiation, T-Lymphocyte
B-Lymphocytes
B7-1 Antigen
Biocompatible Materials
CD4-Positive T-Lymphocytes
Cancer Vaccines
Cell Line, Tumor
Cell Movement
Collagen
Dendritic Cells
Drug Combinations
Flow Cytometry
Granulocytes
Immunophenotyping
Injections, Subcutaneous
Integrin alpha2
L-Selectin
Laminin
Lectins, C-Type
Lymphocyte Activation
Male
Mice
Mice, Inbred C57BL
Neuroblastoma
Proteoglycans